​

BridgeBio Pharma (BBIO) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

BridgeBio Pharma Revenue Highlights

Latest Revenue (Y)

$362.37M

Latest Revenue (Q)

$108.11M

Main Segment (Y)

Product

Main Geography (Y)

License

BridgeBio Pharma Revenue by Period

BridgeBio Pharma Revenue by Year

DateRevenueChange
2025-12-31$362.37M63.30%
2024-12-31$221.90M2285.27%
2023-12-31$9.30M-88.02%
2022-12-31$77.65M11.38%
2021-12-31$69.72M745.14%
2020-12-31$8.25M-79.66%
2019-12-31$40.56M100.00%
2018-12-31-100.00%
2017-12-31--

BridgeBio Pharma generated $362.37M in revenue during NA 2025, up 63.30% compared to the previous quarter, and up 4392.87% compared to the same period a year ago.

BridgeBio Pharma Revenue by Quarter

DateRevenueChange
2025-09-30$108.11M-2.22%
2025-06-30$110.56M-5.20%
2025-03-31$116.63M1882.88%
2024-12-31$5.88M115.30%
2024-09-30$2.73M26.01%
2024-06-30$2.17M-98.97%
2024-03-31$211.12M11998.57%
2023-12-31$1.75M-57.35%
2023-09-30$4.09M149.30%
2023-06-30$1.64M-10.13%
2023-03-31$1.83M-2.35%
2022-12-31$1.87M453.25%
2022-09-30$338.00K-99.54%
2022-06-30$73.75M4253.36%
2022-03-31$1.69M-86.85%
2021-12-31$12.89M449.74%
2021-09-30$2.34M-95.66%
2021-06-30$54.02M11593.51%
2021-03-31$462.00K278.69%
2020-12-31$122.00K-98.50%
2020-09-30$8.13M100.00%
2020-06-30-100.00%
2020-03-31--100.00%
2019-12-31$13.82M-48.32%
2019-09-30$26.74M100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

BridgeBio Pharma generated $108.11M in revenue during Q3 2025, up -2.22% compared to the previous quarter, and up 4986.67% compared to the same period a year ago.

BridgeBio Pharma Revenue Breakdown

BridgeBio Pharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 21Dec 20Dec 19
License and Service$128.32M---
Product$362.37M$3.79M--
Royalty$11.39M---
License-$65.92M$8.00M$13.80M

BridgeBio Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (72.17%), License and Service (25.56%), and Royalty (2.27%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Mar 23Sep 22Jun 22Mar 22Sep 21Jun 21Sep 20
Product$254.26M$108.11M--$1.46M$759.00K$987.00K----
Royalty$7.11M$4.28M---------
License and Service$120.01M$8.31M$1.83M$338.00K$73.75M------
Royalty Revenue--$1.62M--------
Net Product Revenue--$71.50M$36.74M-------
License-------$235.00K$1.58M$8.00M-

BridgeBio Pharma's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (66.67%), License and Service (31.47%), and Royalty (1.86%).

BridgeBio Pharma Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 19
License$13.80M

BridgeBio Pharma's latest annual revenue breakdown by geography, as of Dec 19: License (100.00%).

Quarterly Revenue by Country

CountryMar 23Sep 22Jun 22Mar 22Sep 21Jun 21Sep 20
License and Service$1.83M$338.00K$73.75M----
Product---$1.46M$759.00K$987.00K-
License---$235.00K$1.58M$8.00M-

BridgeBio Pharma's latest quarterly revenue breakdown by geography, as of Mar 23: License and Service (100.00%).

BridgeBio Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
JAZZJazz Pharmaceuticals$4.27B$1.05B
BMRNBioMarin Pharmaceutical$3.22B$776.13M
EXELExelixis$2.32B$597.75M
MRNAModerna$1.94B$1.02B
IONSIonis Pharmaceuticals$944.00M$156.72M
BBIOBridgeBio Pharma$362.37M$108.11M
ASNDAscendis Pharma$266.72M$95.89M
ROIVRoivant Sciences$124.80M$2.00M
RNAAvidity Biosciences$18.75M$12.47M
RVMDRevolution Medicines--
SMMTSummit Therapeutics--

BBIO Revenue FAQ

What is BridgeBio Pharma’s yearly revenue?

BridgeBio Pharma's yearly revenue for 2025 was $362.37M, representing an increase of 63.30% compared to 2024. The company's yearly revenue for 2024 was $221.9M, representing an increase of 2285.27% compared to 2023. BBIO's yearly revenue for 2023 was $9.3M, representing a decrease of -88.02% compared to 2022.

What is BridgeBio Pharma’s quarterly revenue?

BridgeBio Pharma's quarterly revenue for Q3 2025 was $108.11M, a -2.22% decrease from the previous quarter (Q2 2025), and a 3857.21% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $110.56M, a -5.20% decrease from the previous quarter (Q1 2025), and a 4999.86% increase year-over-year (Q2 2024). BBIO's quarterly revenue for Q1 2025 was $116.63M, a 1882.88% increase from the previous quarter (Q4 2024), and a -44.76% decrease year-over-year (Q1 2024).

What is BridgeBio Pharma’s revenue growth rate?

BridgeBio Pharma's revenue growth rate for the last 3 years (2023-2025) was 3795.17%, and for the last 5 years (2021-2025) was 419.78%.

What are BridgeBio Pharma’s revenue streams?

BridgeBio Pharma's revenue streams in c 25 are License and Service, Product, and Royalty. License and Service generated $128.32M in revenue, accounting 25.56% of the company's total revenue Product generated $362.37M in revenue, accounting 72.17% of the company's total revenue, up 9453.60% year-over-year. Royalty generated $11.39M in revenue, accounting 2.27% of the company's total revenue

What is BridgeBio Pharma’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of BridgeBio Pharma was Product. This segment made a revenue of $362.37M, representing 72.17% of the company's total revenue.